Genmab — Februar 2017
-
Regarding Bongobob's (link) Something to think about: in the ASH questioner where doctors could respond to which combo they would use for 2nd line MM patients the DARA POM DEX combo scored 23% and was the 2nd treatment of choice. First was DARA LEN DEX with 34%
-
DARA POM DEX isn’t approved yet, which means that we’ll only see the sales generated by this combo in the JnJ quarterly update and not in the Symphony Health monthly update. Seen a substantial number of patients will be treated with this not yet approved combo it could be that the monthly Symphony Health number will be lower than expected and that we’ll only see the true impact with the quarterly JnJ numbers or the monthly data will already be good / fantastic and we’ll get a big surprise
-
with the quarterly JnJ numbers. Interesting to keep in mind
-
That's indeed what I'm trying to say. Seen some doctors already pointed out that the DaraPomDex combo has their preference. And looking at the post at Myeloma Beacon, off course N=1 but my guess would be that there's already substantial off label sales driven by DaraPomDex
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind